Radiological outcome of bone disease in multiple myeloma patients pre- and post therapy: A single center experience

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Figure 1
- Distribution of patient responses during second positron emission tomography computed tomography (PET CT) scan and end of study. The x-axis represents the clinical responses at the end of the study and y-axis represents no-of patient’s responses during second PET scan.
Download figure
Open in new tab
Download powerpoint
Figure 2
- Distribution of patient responses during third positron emission tomography computed tomography (PET CT) scan and end of study. The x-axis represents the clinical responses at the end of the study and y-axis represents no-of patient’s responses during third PET scan.
Download figure
Open in new tab
Download powerpoint
Figure 3
- Comparison of Maximum SUV values with clinical disease status at the end of the study.

Table 1

- Demographics and disease characteristics.

Table 2

- Laboratory data and cytogenetics abnormalities.

Monoclonal protein variables and cytogenetic characteristics	n (%)
IgG, median (Q1,Q3)	14.6 (7.42, 25.70)
IgM, median (Q1,Q3)	0.3 (0.17, 0.60)
IgA, median (Q1,Q3)	1.7 (0.60, 2.95)
*Immunofixation, n (%)*
Present	27 (73)
Absent	10 (27)
Kappa, median (Q1,Q3)	20.2 (2.97, 155.00)
Lambda, median (Q1,Q3)	9.5 (1.74, 25.60)
Kappa/Lambda ratio, median (Q1,Q3)	3.2 (0.68, 30.61)
LDH, mean±SD	209.2 (115.87)
Beta micro globulin, Median (Q1,Q3)	4.3 (2.11, 7.39)
*Cytogenetics, n (%)*
Normal	26 (56.5)
Abnormal	20 (43.5)
*Type of abnormal cytogenetic, n (%)*
No abnormality	26 (56.5)
Hyperdiploidy	10 (21.7)
Hypodiploidy	4 (08.7)
t(11;14)	1 (02.2)
Deletion of chromosome 17	1 (02.2)
Monosomy 13	1 (02.2)
Rearrangement Igh gene and ccnd1 gene	1 (02.2)

Table 3

- Distribution of positron emission tomography/computed tomography (PET/CT) findings on different body involved areas (N=39).

Parameters	First PET/CT(n=37)	Second PET/CT(n=37)	Third PET/CT(n=20)
PET/CT done	37 (100)	37 (100)	20 (100)
*Therapy status*
Post chemotherapy	37 (100)	37 (100)	20.0 (100)
*Number of lesions*
<5	12 (32.4)	19 (51.6)	6.0(30.0)
≥5 and <10	5 (13.5)	6 (18.2)	0
≥10	19 (51.4)	4 (12.1)	2.0(10.0)
No bony lesion	1 (2.7)	8 (21.6)	12.0(60.0)
Skull, mean±SD	2.6±6.02	0.2±1.04	0.3±1.52)
Spine, mean±SD	6.5±6.95	2.3±3.00	1.8±2.72)
Upper limbs including scapula, mean±SD	5.1±8.51	2.2±6.97	0.9±2.45
Lower limbs, mean±SD	4.8±9.14	1.5±4.52	0.8±2.31
Pelvic bones, mean±SD	7.1±8.10	2.4±2.66	1.9±2.42
Ribs + sternum, mean±SD	6.3±5.50	2.16±2.58	1.9±2.59
*Patterns of bone lesion*
Lytic	19 (51.4)	17 (46.0)	12 (60.0)
lytic lesion with soft tissue	12 (32.4)	4 (10.8)	1 (5.0)
Lytic and sclerotic	3 (8.1)	12 (32.4)	5 (25.0)
Sclerotic	1 (2.7)	2 (5.4)	1 (5.0)
Diffuse osteopenia	1 (2.7)	0.0
No bone lesion	1 (2.7)	2 (5.4)	1 (5.0)
Lymph nodes (presents)	2 (5.4)	2 (5.4)	1 (5.0)
*Organs involved*
No organ involved	30 (81.1)	0	19 (95.0)
Liver	2 (5.4)	2 (5.4)	1 (5.0)
Spleen	2 (5.4)	30 (81.1)	0
Soft tissue	1(2.7)	5 (13.5)	0
Nasopharynx and lungs	1 (2.7)	0	0
Pancreas	1 (2.7)	0	0